ABCB1 p.Thr1065Gly
| Predicted by SNAP2: | A: D (59%), C: D (53%), D: D (66%), E: D (66%), F: N (53%), G: D (59%), H: N (66%), I: D (59%), K: N (53%), L: D (66%), M: N (66%), N: D (53%), P: D (71%), Q: D (59%), R: D (59%), S: N (78%), V: D (53%), W: D (71%), Y: N (57%), |
| Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, S: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Clinical pharmacogenetics in pediatric patients. Pharmacogenomics. 2007 Oct;8(10):1403-11. Husain A, Loehle JA, Hein DW
Clinical pharmacogenetics in pediatric patients.
Pharmacogenomics. 2007 Oct;8(10):1403-11., [PMID:17979513]
Abstract [show]
Pediatric pharmacogenetic studies have the potential to improve the quality of medical care for children. The pediatric population presents a unique pharmacogenetic challenge as children have the additional complexity of ontological phenotypes that impact their drug response. Prescribing medications in children has historically been largely empirical, but utilization of pharmacogenetic information will allow pediatricians to gain key information regarding which patients are best suited for a particular therapeutic agent and which patients may be at risk for serious potentially life-threatening complications from standard treatment regimens. Although large, prospective, multisite investigators are still needed, we illustrate selective clinical examples of the pharmacogenetics for treatment of transplantation, asthma, leukemia and attention-deficit hyperactivity disorder in pediatric patients.
Comments [show]
None has been submitted yet.
No. Sentence Comment
137 A significant genotype-dose interaction and small to moderately favorable effects across all ratings for the T1065G SNP suggest that subjects homozygous for the T allele have improved dose responses in comparison with the variant G allele [62].
X
ABCB1 p.Thr1065Gly 17979513:137:109
status: NEW